Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial.
Alzheimers Dement (N Y)
; 4: 499-507, 2018.
Article
in En
| MEDLINE
| ID: mdl-30364572
ABSTRACT
INTRODUCTION:
Hearing impairment is highly prevalent and independently associated with cognitive decline. The Aging and Cognitive Health Evaluation in Elders study is a multicenter randomized controlled trial to determine efficacy of hearing treatment in reducing cognitive decline in older adults. Clinicaltrials.gov Identifier NCT03243422.METHODS:
Eight hundred fifty participants without dementia aged 70 to 84 years with mild-to-moderate hearing impairment recruited from four United States field sites and randomized 11 to a best-practices hearing intervention or health education control. Primary study outcome is 3-year change in global cognitive function. Secondary outcomes include domain-specific cognitive decline, incident dementia, brain structural changes on magnetic resonance imaging, health-related quality of life, physical and social function, and physical activity.RESULTS:
Trial enrollment began January 4, 2018 and is ongoing.DISCUSSION:
When completed in 2022, Aging and Cognitive Health Evaluation in Elders study should provide definitive evidence of the effect of hearing treatment versus education control on cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment.
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
/
Guideline
/
Risk_factors_studies
Language:
En
Journal:
Alzheimers Dement (N Y)
Year:
2018
Type:
Article
Affiliation country:
United States